{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:39:27Z","timestamp":1782441567037,"version":"3.54.5"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Specific University Research","award":["MUNI\/A\/1558\/2023"],"award-info":[{"award-number":["MUNI\/A\/1558\/2023"]}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Czech Republic","award":["NU23-08-00241"],"award-info":[{"award-number":["NU23-08-00241"]}]},{"name":"National Institute for Cancer Research","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multidisciplinary molecular tumor boards (MTB) are already well established in many comprehensive cancer centers and play an important role in the individual treatment planning for cancer patients. Comprehensive genomic profiling of tumor tissue based on next-generation sequencing is currently performed for diagnostic and mainly predictive testing. If somatic genomic variants are identified, which are suspected to be pathogenic germline variants (PGVs), MTB propose genetic counseling and germline DNA testing. Commonly used comprehensive genomic profiling approaches of tumor tissue do not include a matched germline DNA control. Therefore, the detection of PGVs could be only predicted based on the content of tumor cells (CTC) in selected tumor area (%) and variant allele frequency score (%). For conclusion, the role of a medical geneticist is essential in these cases. The overall prevalence of PGVs in patients with pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) is approximately 10%. In this single-center study, we present 37 patients with PDAC and 48 patients with CRC who were presented at MTB and tested using the large combined DNA\/RNA sequencing panel. Content of tumor cells and variant allele frequency scores were evaluated in all tested patients. In case of suspicion of PGV and no previous genetic testing based on the standard guidelines, genetic counseling was recommended regardless of age, sex, and family history. In the PDAC subgroup, five patients were recommended by MTB for genetic counseling based on suspicious genetic findings. Based on a medical geneticist\u2019s decision, germline DNA sequencing was performed in four of these cases, and all of them tested positive for PGV in the following genes: ATM, ATM, BRCA1, and BRCA2. In the CRC subgroup, no PGV was confirmed in the two patients genetically tested based on the MTB recommendations. Furthermore, we present data from our center\u2019s registry of patients with PDAC and CRC who underwent genetic counseling and germline DNA testing based on the standard screening criteria. Our data confirm that comprehensive genomic profiling of tumor tissue can identify patients with hereditary forms of PDAC, who could remain unidentified by standard screening for hereditary forms of cancer.<\/jats:p>","DOI":"10.1093\/mutage\/geae014","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T05:56:24Z","timestamp":1716357384000},"page":"20-29","source":"Crossref","is-referenced-by-count":2,"title":["Incidental germline findings during comprehensive genomic profiling of pancreatic and colorectal cancer: single-centre, molecular tumour board experience"],"prefix":"10.1093","volume":"40","author":[{"given":"Michal","family":"Eid","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Trizuljak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Taslerova","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gryc","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Vlazny","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Vilmanova","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Jelinkova","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Homolova","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stepan","family":"Tucek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hlavsa","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Grolich","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"Kala","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zdenek","family":"Kral","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4433-5326","authenticated-orcid":false,"given":"Ondrej","family":"Slaby","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University , Brno ,","place":["Czech Republic"]},{"name":"Department of Molecular Medicine, Central European Institute of Technology, Masaryk University , Brno ,","place":["Czech Republic"]},{"name":"Department of Biology, Faculty of Medicine, Masaryk University , Brno,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"2025031622570856400_CIT0001","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14740\/wjon1166","article-title":"Epidemiology of pancreatic cancer: global trends, etiology and risk factors","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"2025031622570856400_CIT0002","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025031622570856400_CIT0003","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1097\/MPA.0000000000001133","article-title":"Long-term survivors of pancreatic cancer","volume":"47","author":"Kardosh","year":"2018","journal-title":"Pancreas"},{"key":"2025031622570856400_CIT0004","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025031622570856400_CIT0005","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/SLA.0000000000004147","article-title":"Actual five-year survival after upfront resection for pancreatic ductal adenocarcinoma: Who beats the odds","volume":"275","author":"Strobel","year":"2022","journal-title":"Ann Surg"},{"key":"2025031622570856400_CIT0006","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025031622570856400_CIT0007","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2025031622570856400_CIT0008","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/cancers11070976","article-title":"Locally advanced pancreatic cancer: work-up, staging, and local intervention strategies","volume":"11","author":"van Veldhuisen","year":"2019","journal-title":"Cancers (Basel)."},{"key":"2025031622570856400_CIT0009","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"key":"2025031622570856400_CIT0010","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2025031622570856400_CIT0011","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.3390\/jcm12052072","article-title":"Stage IV colorectal cancer management and treatment","volume":"12","author":"Hernandez Dominguez","year":"2023","journal-title":"J Clin Med"},{"key":"2025031622570856400_CIT0012","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/bjs5.50299","article-title":"Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study","volume":"4","author":"V\u00e4yrynen","year":"2020","journal-title":"BJS Open"},{"key":"2025031622570856400_CIT0013","author":"Cancer of the Colon and Rectum - Cancer Stat Facts"},{"key":"2025031622570856400_CIT0014","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types","volume":"2","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2025031622570856400_CIT0015","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/cncr.31242","article-title":"Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy","volume":"124","author":"Dudley","year":"2018","journal-title":"Cancer"},{"key":"2025031622570856400_CIT0016","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1016\/j.cgh.2021.04.013","article-title":"Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multicenter prospective study","volume":"20","author":"Uson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025031622570856400_CIT0017","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma","volume":"33","author":"Holter","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025031622570856400_CIT0018","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025031622570856400_CIT0019","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","article-title":"Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative","volume":"24","author":"Pishvaian","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025031622570856400_CIT0020","doi-asserted-by":"publisher","first-page":"e24175","DOI":"10.7759\/cureus.24175","article-title":"Genomic landscape of actionable mutations in primary and metastatic tissues of colon adenocarcinoma","volume":"14","author":"Yeked\u00fcz","year":"2022","journal-title":"Cureus"},{"key":"2025031622570856400_CIT0021","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"2025031622570856400_CIT0022","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1001\/jama.2023.9526","article-title":"Germline genetic testing after cancer diagnosis","volume":"330","author":"Kurian","year":"2023","journal-title":"JAMA"},{"key":"2025031622570856400_CIT0023","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/s0016-5085(99)70510-x","article-title":"New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC","volume":"116","author":"Vasen","year":"1999","journal-title":"Gastroenterology"},{"key":"2025031622570856400_CIT0024","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C-Mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N Engl J Med"},{"key":"2025031622570856400_CIT0025","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without Cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N Engl J Med"},{"key":"2025031622570856400_CIT0026","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1158\/1538-7445.AM2022-3597","article-title":"Abstract 3597: direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor","volume":"82","author":"Koltun","year":"2022","journal-title":"Cancer Res"},{"key":"2025031622570856400_CIT0027","doi-asserted-by":"publisher","first-page":"300628","DOI":"10.1016\/j.hpr.2022.300628","article-title":"HER2 (ERBB2) alterations in colorectal cancers","volume":"28","author":"Tavberidze","year":"2022","journal-title":"Human Pathol Rep"},{"key":"2025031622570856400_CIT0028","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/gm482","article-title":"Clinical and molecular characterization of HER2 amplified-pancreatic cancer","volume":"5","author":"Chou","year":"2013","journal-title":"Genome Med"},{"key":"2025031622570856400_CIT0029","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025031622570856400_CIT0030","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"key":"2025031622570856400_CIT0031","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients With HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025031622570856400_CIT0032","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/bjc.2012.18","article-title":"Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer","volume":"106","author":"Harder","year":"2012","journal-title":"Br J Cancer"},{"key":"2025031622570856400_CIT0033","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.3390\/ijms20215369","article-title":"BRAF-mutated colorectal cancer: clinical and molecular insights","volume":"20","author":"Caputo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025031622570856400_CIT0034","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1159\/000510096","article-title":"Metastatic pancreatic cancer with BRAF and P53 mutations: case report of therapeutic response to doublet targeted therapy","volume":"13","author":"Sasankan","year":"2020","journal-title":"Case Rep Oncol"},{"key":"2025031622570856400_CIT0035","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial","volume":"29","author":"Tian","year":"2023","journal-title":"Nat Med"},{"key":"2025031622570856400_CIT0036","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat Med"},{"key":"2025031622570856400_CIT0037","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00280-021-04234-0","article-title":"BRAF\/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series","volume":"87","author":"Butt","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025031622570856400_CIT0038","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"2025031622570856400_CIT0039","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/s1097-2765(01)00174-5","article-title":"BRCA2 is required for homology-directed repair of chromosomal breaks","volume":"7","author":"Moynahan","year":"2001","journal-title":"Mol Cell"},{"key":"2025031622570856400_CIT0040","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/s1097-2765(00)80202-6","article-title":"Brca1 controls homology-directed DNA repair","volume":"4","author":"Moynahan","year":"1999","journal-title":"Mol Cell"},{"key":"2025031622570856400_CIT0041","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2025031622570856400_CIT0042","first-page":"1120","article-title":"BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II)","volume":"58","author":"Husain","year":"1998","journal-title":"Cancer Res"},{"key":"2025031622570856400_CIT0043","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O\u2019Reilly","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025031622570856400_CIT0044","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00280-015-2788-6","article-title":"Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma","volume":"76","author":"Fogelman","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025031622570856400_CIT0045","doi-asserted-by":"publisher","first-page":"PO.17.00316","DOI":"10.1200\/PO.17.00316","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2018","author":"Shroff","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2025031622570856400_CIT0046","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/jnci\/djab170","article-title":"Are Homologous recombination deficiency mutations relevant in colorectal cancer","volume":"114","author":"Lee","year":"2021","journal-title":"JNCI"},{"key":"2025031622570856400_CIT0047","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/jclinpath-2021-207781","article-title":"Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature","volume":"76","author":"Allen","year":"2023","journal-title":"J Clin Pathol"},{"key":"2025031622570856400_CIT0048","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1002\/cam4.4561","article-title":"NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability","volume":"11","author":"Wang","year":"2022","journal-title":"Cancer Med"},{"key":"2025031622570856400_CIT0049","doi-asserted-by":"publisher","first-page":"PO.21.00089","DOI":"10.1200\/PO.21.00089","article-title":"Impact of disease evolution on efficacy outcomes from larotrectinib in patients with locally advanced or metastatic tropomyosin receptor kinase fusion\u2013positive solid tumors","volume":"5","author":"Bokemeyer","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2025031622570856400_CIT0050","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"key":"2025031622570856400_CIT0051","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/1078-0432.CCR-11-1469","article-title":"Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications","volume":"18","author":"Sinicrope","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025031622570856400_CIT0052","doi-asserted-by":"publisher","first-page":"97","DOI":"10.23750\/abm.v89i9-S.7960","article-title":"Microsatellite instability in colorectal cancer","volume":"89","author":"Gian","year":"2018","journal-title":"Acta Biomed"},{"key":"2025031622570856400_CIT0053","first-page":"1122","article-title":"NCCN Guidelines\u00ae Insights: Genetic\/Familial High-Risk Assessment: Colorectal, Version 1.2021","volume-title":"J Natl Compr Canc Netw","author":"Weiss","year":"2021"},{"key":"2025031622570856400_CIT0054","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2025031622570856400_CIT0055","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025031622570856400_CIT0056","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Mutagenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mutage\/advance-article-pdf\/doi\/10.1093\/mutage\/geae014\/58337010\/geae014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mutage\/article-pdf\/40\/1\/20\/58337010\/geae014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mutage\/article-pdf\/40\/1\/20\/58337010\/geae014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T22:57:32Z","timestamp":1742165852000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mutage\/article\/40\/1\/20\/7679188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,5,22]]},"published-print":{"date-parts":[[2025,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/mutage\/geae014","relation":{},"ISSN":["0267-8357","1464-3804"],"issn-type":[{"value":"0267-8357","type":"print"},{"value":"1464-3804","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,5,22]]}}}